Ipsen SA : * Lexicon Pharmaceuticals and Ipsen enter into ex-North America/Japan licensing and commercialization agreement for telotristat etiprate* Ipsen to commercialize telotristat etiprate outside of North America and Japan* Lexicon retains sole rights to commercialize telotristat etiprate in United States, Canada and Japan Source text for Eikon: Further company coverage: (Gdynia Newsroom: +48 58 698 39 20; Gdynia.newsroom@thomsonreuters.com)
Lexicon Pharmaceuticals, Inc. (Lexicon Pharmaceuticals) is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Shares of LXRX traded higher by 2.27% or $0.03/share to $1.35. In the past year, the shares have traded as low as $1.04 and as high as $2.57. On average, 852225 shares of LXRX exchange hands on a given day and today's volume is recorded at 1123831.
Source
